
Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune organoids—functioning in-vitro replicas of human lymph nodes—combined with AI and high-throughput automation to design and test immunotherapies that work in humans from the start. This approach transcends traditional animal models, which are poor predictors of human outcomes, enabling faster, cheaper, and more effective drug development with reduced risk and cost. Parallel Bio's technology allows for population-scale testing, modeling diverse human immune responses to create safer and more effective therapies. The company actively collaborates with major pharmaceutical and biotech companies, aiming to transform immunotherapy discovery and accelerate the delivery of treatments for previously untreatable diseases. Founded in 2021 and based in Cambridge, Massachusetts, Parallel Bio leverages cutting-edge bioengineering, machine learning, and robotics to revolutionize drug discovery by providing a clinical trial in a dish.

Parallel Bio is a biotechnology company that has developed the first platform replicating the human immune system in a dish for drug discovery and development. Their platform uses immune organoids—functioning in-vitro replicas of human lymph nodes—combined with AI and high-throughput automation to design and test immunotherapies that work in humans from the start. This approach transcends traditional animal models, which are poor predictors of human outcomes, enabling faster, cheaper, and more effective drug development with reduced risk and cost. Parallel Bio's technology allows for population-scale testing, modeling diverse human immune responses to create safer and more effective therapies. The company actively collaborates with major pharmaceutical and biotech companies, aiming to transform immunotherapy discovery and accelerate the delivery of treatments for previously untreatable diseases. Founded in 2021 and based in Cambridge, Massachusetts, Parallel Bio leverages cutting-edge bioengineering, machine learning, and robotics to revolutionize drug discovery by providing a clinical trial in a dish.
Founded: 2021
Headquarters: Cambridge / Watertown, Massachusetts
Product: Human immune organoids + AI + automation for 'trial-in-a-dish' drug discovery
Recent financing: Series A announced Jun 11, 2025 (lead: AIX Ventures)
Preclinical immunotherapy discovery and safety prediction where animal models are poor predictors of human immune responses.
2021
Biotechnology
21000000
Series A announced Jun 11, 2025
“Includes venture firms and notable angel/backers such as AIX Ventures, Refactor Capital, Breakout Ventures, Y Combinator, Jeff Dean, and Marc Benioff”
| Company |
|---|
At Parallel Bio, we are leveraging the human immune system to unlock safer, more effective drugs. We believe immunotherapies are the future of medicine, but their discovery is hindered by outdated models that fail to capture the complexity of the human immune system.
Our platform overcomes these challenges by combining best-in-class human immune organoids with massive scale and advanced computational methods, including AI and machine learning. This allows us to generate unprecedented, population-scale insights into human health and disease.
We can rapidly discover new drugs that we know will work in patients from the start and understand how they will perform across an entire population—something not possible with today's technology. This knowledge will allow us to engineer therapies that will work for as many people as possible, ensuring a safe and effective cure for everyone.
We are a fast-paced, venture-backed company at a pivotal moment of growth. Join us on our journey as we create new tools to push the boundaries of what is possible.
The Role Parallel Bio is building the foundation model for human drug response, trained on patient-derived organoid data at unprecedented scale. We are a multi-site team operating automated wet labs, managing PHI under HIPAA, and scaling rapidly.
We are looking for our first dedicated IT hire to own corporate IT end-to-end across identity, devices, SaaS platforms, network infrastructure, and end-user support. This is a hands-on role today with a clear path toward building the IT function as we scale.
You will inherit a functioning stack along with active vendor engagements for network infrastructure and endpoint/identity security. Your job is to operationalize what exists, rationalize what is fragmented, and own these vendor relationships with an eye toward evolving our approach as the company grows.
This role is for someone who can troubleshoot a WiFi issue in the morning, negotiate a vendor contract at lunch, and draft a multi-site IT roadmap in the afternoon. You should be organized, technically capable, and comfortable operating across strategic and tactical work.
What You'll Own Day-to-Day IT Operations
Tech Stack Rationalization & Implementation
Network Infrastructure
Security & Compliance
Vendor & Stakeholder Management
Qualifications Required
Nice to Have
Parallel Bio is an equal opportunity employer committed to fostering an inclusive and respectful workplace. We encourage applications from individuals of all backgrounds, regardless of age, gender, ethnicity, religion, disability, or sexual orientation. Compensation Range: $147K - $160K